JVJoseph M. Venturini

Joseph M. Venturini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph M. Venturini has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safe and rapid radial hemostasis achieved using a novel topical hemostatic patch: Results of a first‐in‐human pilot study using hydrophobically modified polysaccharide‐chitosan

    by Rajeev Anchan, Joseph Venturini, Paul Larsen, Linda Lee, Christopher Fernandez, Stephanie A. Besser, Rohan Kalathiya, Jonathan Paul, John Blair, Sandeep Nathan

    Background: The transradial approach (TRA) for catheter interventions decreases vascular complications and bleeding versus transfemoral approach. Reducing time to hemostasis and preventing radial artery occlusion (RAO) following TRA are important and incompletely realized aspirations.Objectives: This first‐in‐human study sought to evaluate the efficacy of a novel, topically applied compound (hydrophobically modified polysaccharide‐chitosan, hm‐P) plus minimal required pneumatic compression, to achieve rapid radial arterial hemostasis in post‐TRA procedures compared with de facto standards.Materials and Methods: About 50 adult patients undergoing 6 French diagnostic TRA procedures were prospectively enrolled. At procedure completion, a topical hm‐P impregnated patch was placed over the dermotomy and TR Band (TRB) compression was applied to the access site. This patch was used as part of a novel rapid deflation protocol with a primary outcome of time to hemostasis. Photographic and vascular ultrasound evaluation of the radial artery was performed to evaluate the procedural site.Results: Time to hemostasis was 40.5 min (IQR: 38–50 min) with the majority of patients (n = 39, 78%) not requiring reinflation. Patients with bleeding requiring TRB reinflation were more likely to have low body weight and liver dysfunction, with absence of hypertension and LV dysfunction. The rate of RAO was 0% with predischarge radial artery patency documented in all patients using vascular ultrasound. One superficial hematoma was noted. No late bleeding events or cutaneous reactions were reported in the study follow‐up.Conclusions: Topical application of hm‐P in conjunction with pneumatic compression was safe and resulted in rapid and predictable hemostasis at the arterial puncture site.


  • Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease

    by AbdulRahman Dia, Joseph M. Venturini, Rohan Kalathiya, Stephanie Besser, Raider Estrada, Janet Friant, Jonathan Paul, John E. Blair, Sandeep Nathan, Atman P. Shah

    Objectives: To assess the safety and efficacy of the Absorb bioresorbable vascular scaffold (BVS) in complex, infrapopliteal lesions for the management of chronic limb ischemia.Background: The interventional management of infrapopliteal PAD remains challenging due to high restenosis rates with metallic drug‐eluting stents and balloon angioplasty. Metallic stents are associated with impaired vessel vasomotor tone, remodeling, autoregulation, and long‐term inflammation. BVSs are biodegradable scaffolds that provide short‐term vascular support before degrading to allow restoration of vasomotor tone and endothelial function. A recent trial reported excellent 12‐month vessel patency rates in simple infrapopliteal arterial lesions treated with Absorb BVS.Methods: This single‐center, retrospective study evaluated the use of the Absorb BVS (everolimus impregnated poly‐L‐lactic scaffold) in patients with infrapopliteal PAD with respect to safety (thrombosis and TIMI bleeding), technical success, and clinically driven target vessel failure (CD‐TVF) at 12 months.Results: Thirty‐one patients (51.6% male) with a median age of 67 years with advanced infrapopliteal disease were treated with 49 BVS in 41 vessels. The mean stenosis was 94% (80–100), with 49% of lesions being CTOs. No scaffold thrombosis or periprocedural bleeding was observed. Procedural success was achieved in all patients. Freedom from CD‐TVF was 95.1% at 12 months driven by one revascularization and one amputation. Primary patency was 96.7% at 12 months. All patients were alive at 12 months, and 96.8% of patients improved their Rutherford–Becker classification.Conclusions: At 12 months, our study found that patients with advanced infrapopliteal PAD who were treated with Absorb BVS reported improved clinical status and a low rate of CD‐TVF.


  • Cost-utility of extracorporeal cardiopulmonary resuscitation in patients with cardiac arrest

    by Murtaza I. Bharmal, Joseph M. Venturini, Rhys F.M. Chua, Willard W. Sharp, David G. Beiser, Corey E. Tabit, Taishi Hirai, Jonathan R. Rosenberg, Janet Friant, John E.A. Blair, et al.